Immunotherapy for Epstein – Barr Virus-Associated Tumors

References

• Tosato, G. (1987) "The Epstein-Barr virus and the immune system", Adv. Canc. Res., 49, 75–125.
   Web of Science ®Google Scholar
• Epstein, M.A., Barr, Y.M. and Achong, B.G. (1964) "Virus particles in cultured lymphoblasts from Burlcitt's lymphoma", Lancet, 1, 702–703.
   Google Scholar
• Longnecker, R. (1998) Molecular Biology of Epstein-Barr Viruss. In Human Tumor Viruses, edited by D. McCance, Washington: American Society of Microbiology Press.
   Google Scholar
• Wallace, L.E., Rowe, M., Gaston, JS., Ricicinson, A.B. and Epstein, M.A. (1982) "Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cyto-toxic T cell lines using interleukin 2", Eur. J. Immunol., 12, 1012 — 1018.
   Web of Science ®Google Scholar
• Strang, G. and Ricicinson, A.B. (1987) "Multiple HLA class I-dependent cytotoxicities constitute the 'non-HLA-restricted' re-sponse in infectious mononucleosis", Eur. J. Immunol., 17, 1007 — 1013.
   Web of Science ®Google Scholar
• Murray, R.J., Kurilla, M.G., Brooks, J.M., Thomas, W.A., Rowe, M., Kieff, E., et al. (1992) "Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies", J. Exp. Med., 176, 157–168.
   PubMed Web of Science ®Google Scholar
• Marshall, N.A., Howe, J.G., Formica, R., Krause, D., Wagner, J.E., Berliner, N., et al. (2000) "Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation", Blood, 96, 2814 — 2821.
   Google Scholar
• Curtis, R.E., Travis, L.B., Rowlings, P.A., Socie, G., Kingma, D.W., Banks, P.M., et al. (1999) "Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study", Blood, 94, 2208 — 2216.
   PubMed Web of Science ®Google Scholar
• Gross, T.G., Steinbuch, M., DeFor, T., Shapiro, R.S., McGlave, P., Ramsay, N.K., et al. (1999) "B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome", Bone Marrow Transplant, 23, 251— 258.
   PubMed Web of Science ®Google Scholar
• Zutter, M.M., Martin, P.J., Sale, G.E., Shulman, H.M., Fisher, L., Thomas, E.D., et al. (1988) "Epstein-Barr virus lymphoproliferation after bone marrow transplantation", Blood, 72, 520–529.
   Google Scholar
• Lucas, KG., Small, T.N., Heller, G., Dupont, B. and O'Reilly, R.J. (1996) "The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation", Blood, 87, 2594 — 2603.
   Google Scholar
• Fischer, A., Blanche, S., Le Bidois, J., Bordigoni, P., Gamier, J.L., Niaudet, P., et al. (1991) "Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation", N. Engl. J. Med., 324, 1451–1456.
   Google Scholar
• Meij, P., van Esser, J.W., Niesters, H.G., van Baarle, D., Miedema, F., Blake, N., et al. (2003) "Impaired recovery of Epstein-Barr virus (EBV)— specific CD8 + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease", Blood, 101, 4290–4297.
   PubMed Web of Science ®Google Scholar
• Swerdlow, S.H. (1992) "Post-transplant lymphoproliferative dis-orders: a morphologic, phenotypic and genotypic spectrum of disease", Histopathol., 20, 373— 385.
   Google Scholar
• Chadburn, A., Suciu-Foca, N., Cesarman, E., Reed, E., Michler, R.E. and Knowles, D.M. (1995) "Post-transplantation lymphopro-liferative disorders arising in solid organ transplant recipients are usually of recipient origin", Am. J. Pathol., 147, 1862–1870.
   Google Scholar
• Nalesnik, MA. (1997) "Clinicopathologic features of posttrans-plant lymphoproliferative disorders", Ann. Transplant., 2, 33–40.
   Google Scholar
• Collins, M.H., Montone, K.T., Leahey, A.M., Hodinka, R.L., Salhany, K.E., Kramer, D.L., et al. (2001) "Post-transplant lymphoproliferative disease in children. [see comment]", Pediatr. Transplant., 5, 250–257.
   Web of Science ®Google Scholar
• Finn, L., Reyes, J., Bueno, J. and Yunis, E. (1998) "Epstein-Barr virus infections in children after transplantation of the small intestine", Am. J. Surg. Pathol., 22, 299–309.
   PubMed Web of Science ®Google Scholar
• Swinnen, L.J., Costanzo-Nordin, MR., Fisher, S.G., O'Sullivan, E.J., Johnson, MR., Heroux, AL., et al. (1990) "Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipi-ents", N. Engl. J. Med., 323, 1723–1728.
   PubMed Web of Science ®Google Scholar
• Ho, M. (1995) "Risk factors and pathogenesis of posttransplant lymphoproliferative disorders", TranspL Proc., 27, 38–40.
   PubMed Web of Science ®Google Scholar
• Sparano, JA., Hu, X., Wiernik, P.H., Sarta, C., Reddy, D.M., Hanau, L., et al. (1997) "Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy", J. Nat. Canc. Inst., 89, 301–307.
   PubMed Web of Science ®Google Scholar
• Tirelli, U., Errante, D., Spina, M., Vaccher, E., Serraino, D., Boiocchi, M., et al. (1996) "Long-term survival of patients with HIV-related systemic non-Hodgkin's lymphomas", Hematol. On-col., 14, 7 — 15.
   Google Scholar
• Forsyth, P.A. and DeAngelis, L.M. (1996) "Biology and manage-ment of AIDS-associated primary CNS lymphomas", Hematology—Oncology Clinics of North America, 10, 1125–1134.
   PubMed Web of Science ®Google Scholar
• MacMahon, EM., Glass, JD., Hayward, S.D., Mann, R.B., Becker, P.S., Charache, P., et al. (1991) "Epstein-Barr virus in AIDS-related primary central nervous system lymphoma", Lancet, 338, 969 — 973.
   Google Scholar
• Nakhleh, RE., Manivel, J.C., Hurd, D. and Sung, J.H. (1989) "Central nervous system lymphomas. Immunohistochemical and clinicopathologic study of 26 autopsy cases", Archives of Pathology & Laboratory Medicine, 113, 1050— 1056.
   Google Scholar
• Camilleri-Broet, S., Davi, F., Feuillard, J., Seilhean, D., Michiels, J.F., Brousset, P., et al. (1997) "AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors", Hum. Pathol., 28, 367–374.
   Web of Science ®Google Scholar
• Camilleri-Broet, S., Davi, F., Feuillard, J., Bourgeois, C., Seilhean, D., Hauw, ii., et al. (1995) "High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas", Blood, 86, 432–435.
   PubMed Web of Science ®Google Scholar
• Corn, B.W., Donahue, B.R., Rosenstock, J.G., Cooper, JS., Xie, Y., Brandon, A.H., et al. (1997) "Palliation of AIDS-related primary lymphoma of the brain: observations from a multi-institutional database", Int. J. Radiat. OncoL Biol. Phys., 38, 601— 605.
   Google Scholar
• Chamberlain, M.C. (1994) "Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma", Cancer, 73, 1728–1730.
   Web of Science ®Google Scholar
• Weiss, L.M., Strickler, J.G., Warnke, R.A., Purtilo, D.T. and Sklar, J. (1987) "Epstein-Barr viral DNA in tissues of Hodgkin's disease", Am. J. Pathol., 129, 86–91.
   Web of Science ®Google Scholar
• Weiss, L.M., Movahed, L.A., Wamke, R.A., Sklar, J. (1989) "Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease", N. Engl. J. Med., 320, 502–506.
   Google Scholar
• Rosdahl, N., Larsen, S.O. and Clemmesen, J. (1974) "Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience", BMJ, 2, 253–256.
   PubMed Web of Science ®Google Scholar
• Mueller, N., Evans, A., Harris, N.L., Comstock, G.W., Jellum, E., Magnus, K., et al. (1989) "Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis", N. Engl. J. Med., 320, 689 — 695.
   Google Scholar
• Weiss, L.M. (1992) "Gene analysis and Epstein-Barr viral genome studies of Hodgkin's disease", Int. Rev. Exp. Pathol., 33, 165 — 184.
   Google Scholar
• Bignon, Y.J., Bernard, D., Cure, H., Fonck, Y., Pauchard, J., Travade, P., et al. (1990) "Detection of Epstein-Barr viral genomes in lymph nodes of Hodgkin's disease patients", Mol. Carcinogenesis, 3, 9 —11.
   Web of Science ®Google Scholar
• Uhara, H., Sato, Y., Mukai, K., Akao, I., Matsuno, Y., Furuya, S., et al. (1990) "Detection of Epstein-Barr virus DNA in Reed-Sternberg cells of Hodgkin's disease using the polymerase chain reaction and in situ hybridization", Jpn. J. Cancer Res., 81, 272 — 278.
   Google Scholar
• Weiss, L.M., Chen, Y.Y., Liu, X.F. and Shibata, D. (1991) "Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study", Am. J. PathoL, 139, 1259 — 1265.
   Web of Science ®Google Scholar
• Gianni, A.M., Siena, S., Bregni, M., Lombardi, F., Gandola, L., Di, Nicola, M., et al. (1993) "High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease — a 6-year update", Ann. OncoL, 4, 889— 891.
   Google Scholar
• Nademanee, A., O'Donnell, MR., Snyder, D.S., Schmidt, G.M., Parker, P.M., Stein, AS., et al. (1995) "High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors", Blood, 85, 1381–1390.
   PubMed Web of Science ®Google Scholar
• Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., et al. (1994) "Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoprolifera-tive disorders after allogeneic bone marrow transplantation", N. Engl. J. Med., 330, 1185–1191.
   Google Scholar
• Rooney, CM., Smith, CA., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., et al. (1998) "Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients", Blood, 92, 1549–1555.
   Google Scholar
• Straathof, K.C., Savoldo, B., Heslop, H.E. and Rooney, C.M. (2002) "Immunotherapy for post-transplant lymphoproliferative disease", Br. J. Haematol., 118, 728 — 740.
   Web of Science ®Google Scholar
• Gustafsson, A., Levitsky, V., Zou, J.Z., Frisan, T., Dalianis, T., Ljungman, P., et al. (2000) "Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells", Blood, 95, 807.
   Google Scholar
• Gottschalk, S., Ng, C.Y., Perez, M., Smith, CA., Sample, C., Brenner, M.K., et al. (2001) "An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs", Blood, 97, 835–843.
   Google Scholar
• van Esser, J.W., Niesters, HG., van der, H.B., Meijer, E., Osterhaus, A.D., Gratama, J.W., et al. (2002) "Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular mon-itoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation", Blood, 99, 4364–4369.
   Google Scholar
• Faye, A., Quartier, P., Reguerre, Y., Lutz, P., Carret, AS., Dehee, A., et al. (2001) "Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder fol-lowing stem cell transplantation in children", Br. J. Haematol., 115, 112— 118.
   Web of Science ®Google Scholar
• Starzl, T.E., Nalesnik, MA., Porter, K.A., Ho, M., Iwatsulci, S., Griffith, B.P., et al. (1984) "Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy", Lancet, 1, 583–587.
   Google Scholar
• Haque, T., Amlot, P.L., Helling, N., Thomas, JA., Sweny, P., Rolles, K., et al. (1998) "Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients", J. ImmunoL, 160, 6204–6209.
   PubMed Web of Science ®Google Scholar
• Milpied, N., Vasseur, B., Parquet, N., Gamier, J.L., Antoine, C., Quartier, P., et al. (2000) "Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients", Ann. OncoL, 11(Suppl 1), 113–116.
   Google Scholar
• Ganne, V., Siddiqi, N., Kamaplath, B., Chang, CC., Cohen, E.P., Bresnahan, BA., et al. (2003) "Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproli-ferative disorder", Clin. Transplant., 17, 417–422.
   Web of Science ®Google Scholar
• Dotti, G., Rambaldi, A., Fiocchi, R., Motta, T., Torre, G., Viero, P., et al. (2001) "Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ trans-plant", Haematologica, 86, 618 — 623.
   Google Scholar
• Zompi, S., Tulliez, M., Conti, F., Leblond, V., Gaulard, P., Blanche, P., et al. (2000) "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproli-ferative disorders after orthotopic liver transplantation: a report of three cases", J. Hepatol., 32, 521–527.
   PubMed Web of Science ®Google Scholar
• Gulley, M.L., Swinnen, L.J., Plaisance, K.T. Jr., Schnell, C., Grogan, T.M., Schneider, B.G. and Southwest Oncology Group. (2003) "Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy", Transplant, 76, 959–964.
   PubMed Web of Science ®Google Scholar
• Hague, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P., Iley, A., et al. (2002) "Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells", Lancet, 360, 436–442.
   Google Scholar
• Sun, Q., Burton, R.L., Reddy, V. and Lucas, K.G. (2002) "Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lympho-cytes for patients with refractory EBV-related lymphoma", Br. J. HaematoL, 118, 799–808.
   Web of Science ®Google Scholar
• Roskrow, M.A., Suzuki, N., Gan, Y., Sixbey, J.W., Ng, C.V., Kimbrough, S., et al. (1998) "Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease", Blood, 91, 2925–2934.
   Google Scholar
• Rooney, C.M., Roskrow, M.A., Suzuki, N., Ng, C.V., Brenner, M.K. and Heslop, H. (1998) "Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells", Ann. Oncol., 9(Suppl 5), S129 —S132.
   Google Scholar
• Chapman, A.L.N., Ricicinson, A.B., Thomas, W.A., Jarrett, R.F., Crocker, J. and Lee, S.P. (2001) "Epstein-Barr Virus-specific Cytotoxic T Lymphocyte Responses in the Blood and Tumor Site of Hodgkin's Disease Patients: Implications for a T-cell-based Therapy", Cancer Res., 61, 6219–6226.
   PubMed Web of Science ®Google Scholar
• Slcinnider, B.F., Elia, A.J., Gascoyne, R.D., Patterson, B., Trumper, L., Kapp, U., et al. (2002) "Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma", Blood, 99, 618–626.
   Web of Science ®Google Scholar
• Slcinnider, B.F., Elia, A.J., Gascoyne, RD., Trumper, L.H., von Bonin, F., Kapp, U., et al. (2001) "Interleulcin 13 and interleulcin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma", Blood, 97, 250–255.
   Web of Science ®Google Scholar
• Izban, K.F., Ergin, M., Martinez, R.L. and Alkan, S. (2000) "Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells", Mod. Pathol., 13, 1324— 1331.
   Web of Science ®Google Scholar
• Peh, S.C., Kim, L.H. and Poppema, S. (2001) "TARC, a CC chemolcine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma", Am. J. Surg. Pathol., 25, 925–929.
   PubMed Web of Science ®Google Scholar
• Van den Berg, A., Visser, L. and Poppema, S. (1999) "High expression of the CC chemolcine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodg-kin's lymphoma", Am. J. Pathol., 154, 1685–1691.
   Web of Science ®Google Scholar
• Kapp, U., Yeh, W.C., Patterson, B., Elia, A.J., Kagi, D., Ho, A., et al. (1999) "Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells", J. Exp. Med., 189, 1939 — 1946.
   Web of Science ®Google Scholar
• Lucas, K.G., Salzman, D., Garcia, A. and Sun, Q. (2004) "Adoptive Immunotherapy with Allogeneic Epstein— Barr Virus (EBV)-Spe-cific Cytotoxic T-Lymphocytes for Recurrent, EBV-Positive Hodg-kin Disease", Cancer (in press).
   Google Scholar
• Engert, A., Diehl, V., Schnell, R., Radszuhn, A., Hatwig, MT., Drillich, S., et al. (1997) "A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma", Blood, 89, 403–410.
   PubMed Web of Science ®Google Scholar
• Barth, S., Huhn, M., Matthey, B., Tawadros, S., Schnell, R., Schinkothe, T., et al. (2000) "Ki-4(scFv)-ETA, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice", Blood, 95, 3909 — 3914.
   Google Scholar
• Niedobitek, G. (2000) "Epstein-Barr virus infection in the patho-genesis of nasopharyngeal carcinoma", MoL Pathol., 53, 248 — 254.
   Google Scholar
• Chan, S.H., Day, N.E., Kunaratnam, N., Chia, K.B. and Simons, M.J. (1983) "HLA and nasopharyngeal carcinoma in Chinese—a further study", Intern. J. Canc., 32, 171–176.
   PubMed Web of Science ®Google Scholar
• Parkin, D. (1997) "Epstein-Barr virus", IARC Monogr. EvaL Carcinog. Risks Hum., 70, 47— 373.
   PubMedGoogle Scholar
• zur, H.H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., et al. (1970) "EBV DNA in biopsies of Burlcitt tumours and anaplastic carcinomas of the nasopharynx", Nature, 228, 1056 — 1058.
   Google Scholar
• Huang, D.P., Ho, J.H., Henle, W. and Henle, G. (1974) "Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies", Intern. J. Canc., 14, 580 — 588.
   PubMed Web of Science ®Google Scholar
• Chua, D., Huang, J., Zheng, B., Lau, S.Y., Luk, W., Kwong, D.L., et al. (2001) "Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma", Intern. J. Canc., 94, 73 — 80.
   PubMed Web of Science ®Google Scholar
• Sun, Q., Burton, R.L. and Lucas, K.G. (2002) "Large scale ex vivo expansion of antigen-specific T cells engineered for activation-dependent expression of transgene introduced by lentiviral vector mediated transduction", Blood, 100, 652a.
   Google Scholar
• Bollard, C.M., Rossig, C., Calonge, M.J., Huls, M.H., Wagner, H.J., Massague, J., et al. (2002) "Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity", Blood, 99, 3179 — 3187.
   Google Scholar
• Lee, S.P., Tierney, R.J., Thomas, W.A., Brooks, J.M. and Ricicinson, A.B. (1997) "Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy", J. ImmunoL, 158, 3325–3334.
   PubMed Web of Science ®Google Scholar
• Su, Z., Peluso, M.V., Raffegerst, S.H., Schendel, D.J. and Roskrow, M.A. (2001) "The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease", Eur. J. Immunol., 31, 947–958.
   Web of Science ®Google Scholar